secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001104659-22-118565
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode Q3 operating loss widens to $4.95M; cash $8.8M, runway through Q1 2023
--------------------------------------------------------------------------------

- Q3 operating loss $4.95M vs $2.36M in prior year; R&D expense $3.0M, up from $993K.
- Cash $8.8M at Sept 30 (down from $20.8M); plus ~$928K SBIR grant; expects to fund only through Q1 2023.
- Submitted eIND for Phase 0 trial of lead candidate TTX-MC138; reported preclinical efficacy in pancreatic cancer models.
- FDA granted orphan drug designation for TTX-siPDL1 in pancreatic cancer; strategic alliance with MD Anderson announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465922118565/0001104659-22-118565-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465922118565/tm2230414d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-118565

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer